文献速递心脑血管急症

睾酮替代治疗与雄激素缺乏男性心血管结局的关联

Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
PubMed 文献 · JAMA Intern Med · 2017-01-01
一句话结论在雄激素缺乏男性中,配发睾酮处方与中位随访3.4年内心血管结局风险降低相关(校正HR 0.67)。

这项回顾性队列研究在整合医疗系统内纳入年龄至少40岁、有雄激素缺乏证据(编码诊断和/或晨间血清总睾酮低于300 ng/dL)的男性,比较曾配发睾酮(ever-TRT)与从未配发(never-TRT)者。主要终点为急性心肌梗死、冠状动脉血运重建、不稳定型心绞痛、卒中、短暂性脑缺血发作和心脏性猝死的复合终点。ever-TRT组8808例(19.8%),never-TRT组35527例(80.2%)。中位随访3.4年,复合心血管终点发生率never-TRT组23.9/1000人年 vs ever-TRT组16.9/1000人年,校正HR 0.67(95%CI 0.62-0.73)。

要点

  • 在雄激素缺乏男性中,ever-TRT组复合心血管终点发生率16.9/1000人年 vs never-TRT组23.9/1000人年,校正HR 0.67(95%CI 0.62-0.73)。
  • 卒中/TIA复合终点:ever-TRT组校正HR 0.72(95%CI 0.62-0.84),低于never-TRT组。
  • 心脏事件复合终点(AMI、SCD、不稳定型心绞痛、血运重建):ever-TRT组校正HR 0.66(95%CI 0.60-0.72),低于never-TRT组。
  • ever-TRT组8808例(19.8%),平均年龄58.4岁,1.4%有既往心血管事件;never-TRT组35527例(80.2%),平均年龄59.8岁,2.0%有既往心血管事件。
  • 中位随访:never-TRT组3.2年(IQR 1.7-6.6) vs ever-TRT组4.2年(IQR 2.1-7.8)。

适用人群与场景

  • 年龄至少40岁、有雄激素缺乏证据的男性,证据为编码诊断和/或晨间血清总睾酮水平低于300 ng/dL。
  • 研究在整合医疗系统内进行,纳入时间为1999年1月1日至2010年12月31日,随访至2012年12月31日。

诊断标准与关键阈值

  • 雄激素缺乏:编码诊断和/或晨间血清总睾酮水平低于300 ng/dL。

研究设计与关键结果

  • 回顾性队列研究,纳入8808例ever-TRT组(19.8%)和35527例never-TRT组(80.2%),比较配发睾酮处方(注射、口服或局部)与从未配发者的心血管结局。
  • 主要复合心血管终点(急性心肌梗死、冠状动脉血运重建、不稳定型心绞痛、卒中、短暂性脑缺血发作、心脏性猝死)发生率:never-TRT组23.9/1000人年 vs ever-TRT组16.9/1000人年,校正HR 0.67(95%CI 0.62-0.73)。
  • 卒中/TIA复合终点:ever-TRT组校正HR 0.72(95%CI 0.62-0.84),低于never-TRT组。
  • 心脏事件复合终点(AMI、SCD、不稳定型心绞痛、血运重建):ever-TRT组校正HR 0.66(95%CI 0.60-0.72),低于never-TRT组。
  • 中位随访3.4年:never-TRT组3.2年(IQR 1.7-6.6) vs ever-TRT组4.2年(IQR 2.1-7.8)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在雄激素缺乏男性中,配发睾酮处方与中位随访3.4年内心血管结局风险降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Controversy exists regarding the safety of testosterone replacement therapy (TRT) following recent reports of an increased risk of adverse cardiovascular events.

OBJECTIVE: To investigate the association between TRT and cardiovascular outcomes in men with androgen deficiency.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted within an integrated health care delivery system. Men at least 40 years old with evidence of androgen deficiency either by a coded diagnosis and/or a morning serum total testosterone level of less than 300 ng/dL were included. The eligibility window was January 1, 1999, to December 31, 2010, with follow-up through December 31, 2012.

EXPOSURES: Any prescribed TRT given by injection, orally, or topically.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular end points that included acute myocardial infarction (AMI), coronary revascularization, unstable angina, stroke, transient ischemic attack (TIA), and sudden cardiac death (SCD). Multivariable Cox proportional hazards models were used to investigate the association between TRT and cardiovascular outcomes. An inverse probability of treatment weight, propensity score methodology, was used to balance baseline characteristics.

RESULTS: The cohorts consisted of 8808 men (19.8%) ever dispensed testosterone (ever-TRT) (mean age, 58.4 years; 1.4% with prior cardiovascular events) and 35 527 men (80.2%) never dispensed testosterone (never-TRT) (mean age, 59.8 years; 2.0% with prior cardiovascular events). Median follow was 3.2 years (interquartile range [IQR], 1.7-6.6 years) in the never-TRT group vs 4.2 (IQR, 2.1-7.8) years in the ever-TRT group. The rates of the composite cardiovascular end point were 23.9 vs 16.9 per 1000 person-years in the never-TRT and ever-TRT groups, respectively. The adjusted hazard ratio (HR) for the composite cardiovascular end point in the ever-TRT group was 0.67 (95% CI, 0.62-0.73. Similar results were seen when the outcome was restricted to combined stroke events (stroke and TIA) (HR, 0.72; 95% CI, 0.62-0.84) and combined cardiac events (AMI, SCD, unstable angina, revascularization procedures) (HR, 0.66; 95% CI, 0.60-0.72).

CONCLUSIONS AND RELEVANCE: Among men with androgen deficiency, dispensed testosterone prescriptions were associated with a lower risk of cardiovascular outcomes over a median follow-up of 3.4 years.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Cheetham TC, An J, Jacobsen SJ, et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med. 2017. PMID: 28241244. doi:10.1001/jamainternmed.2016.9546

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。